Careful with attribution. You changed the timing, the dose and the season. That is three variables.

Half of what people describe as tolerance is a change in the underlying condition, and the two need different answers.

Half of what people describe as tolerance is a change in the underlying condition, and the two need different answers.

Reference ranges differ between labs, so comparing two reports is close to meaningless. Currently on a partial order myself.

Narrow conclusion. Four months in on semaglutide and it lines up.

Half of what people describe as tolerance is a change in the underlying condition, and the two need different answers.

Where does the human data stop and the extrapolation begin? That is the whole thread.

Imprint databases are mostly US-centric. A confident hit for another market is still a guess.